Nav: Home

Testing for HPV types 16 and 18 may better inform referral to colposcopy

November 14, 2016

1. Testing for HPV types 16 and 18 in women with high risk HPV may better inform referral to colposcopy

Abstract: http://annals.org/aim/article/doi/10.7326/M16-2735

URLs go live when the embargo lifts

Testing for HPV types 16 and 18 in women with minor cervical lesions may be useful as a second triage after high-risk HPV testing to determine which patients should go on to colposcopy. The results of a systematic review and meta-analysis are published in Annals of Internal Medicine.

Women with minor cervical abnormalities, including atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL), have a modestly increased risk for cervical cancer. Testing for high-risk HPV can be used to triage these women, but most will test positive and referring them all to colposcopy carries a considerable burden and cost. Because HPV types 16 and 18 cause about 70 percent of cervical cancer cases, genotyping for these types of HPV could allow for more precise patient management.

Researchers reviewed 24 moderate- to good-quality published studies involving almost 14,000 women with minor cervical lesions to evaluate the accuracy of genotyping for HPV types 16 and 18 and to determine its utility as a second triage step after high-risk HPV testing. The data suggests that genotyping for HPV 16 and 18 was more efficient compared with high-risk HPV testing, but at the expense of a loss in sensitivity. Since women testing positive for HPV 16 and 18 are at high risk for cervical cancer, they should be referred to colposcopy. The authors suggest that women carrying other high-risk HPV types are at borderline risk and may be referred to colposcopy or retesting, depending on local decision thresholds.

Note: For an embargoed PDF, please contact Cara Graeff. The author's press office can be reached at press@wiv-isp.be or +32 (0)2/642 54 20.

2. Arthritis drug shown to reverse hair loss from alopecia universalis


Abstract: http://annals.org/aim/article/doi/10.7326/L16-0125

URLs go live when the embargo lifts

Tofacitinib, a drug approved to treat moderate to severe rheumatoid arthritis, reversed hair loss for a man and a woman both suffering from alopecia universalis for 10 years. The case report is published in Annals of Internal Medicine.

Alopecia universalies involves complete hair loss in all parts of the body. The cause of alopecia universalis is uncertain, but many investigators believe it to be an autoimmune disease with the patient's immune system directed against the hair follicles. No treatment is effective, although several have been proposed.

A 38-year-old man and a 20-year-old woman for whom initial treatment failed were treated with tofacitinib, 5 mg orally twice daily. Hair partially grew on the scalp, eyebrows, and axillae after 2 months of therapy. No adverse events were observed after 9 months, although long-term therapy with tofacitinib can cause serious adverse events. The researchers believe that these cases should prompt a clinical trial to determine whether tofacitinib is a reasonable treatment for alopecia universalis despite its risk for adverse effects because successful treatment can improve patients' lives dramatically.

Note: For an embargoed PDF, please contact Cara Graeff. To reach the lead author, Dr. Morton Scheinberg, please email Gabriela Scheinberg at gabileder@gmail.com or +55 11 98111-9294.

3. Care in a patient-centered medical home leads to better medication adherence


Abstract: http://annals.org/aim/article/doi/10.7326/M16-2659

Editorial: http://annals.org/aim/article/doi/10.7326/M16-2397

URLs go live when the embargo lifts

Patients initiating treatment for common chronic diseases have better medication adherence when they receive their care in a patient-centered medical home. This is important because medication adherence is a vital measure of health care quality for chronic diseases. The findings are published in Annals of Internal Medicine.

A patient-centered medical home is a care delivery model where patient treatment is coordinated through their primary care physician so that patients get the care they need, when they need it, and in a manner they can understand. While adoption of this care model has been widespread, it has only been evaluated on a few health care quality measures. Researchers sought to determine whether use of a patient-centered medical homes influenced patients' adherence to medications initiated for the treatment of hypertension, diabetes, and high cholesterol in a large nationwide sample of providers and practices. The researchers estimated that patients using medical homes that met National Committee for Quality Assurance (NCQA) criteria had levels of adherence that were about 2 to 3 percent higher than among patients receiving care at other practices. The authors point out that meeting these criteria requires substantial time and effort for a practice. They suggest that these findings have significant implications for providers, health plans, and policymakers who are considering the best potential practices for patients because adherence is an important quality measure.

Note: For an embargoed PDF, please contact Cara Graeff. To reach the lead author, Dr. Niteesh Choudhry, please contact Elaine St. Peter at estpeter@partners.org or 617-525-6375.

4. Patients with HIV now live about as long as their uninfected peers


Abstract: http://annals.org/aim/article/doi/10.7326/L16-0091

URLs go live when the embargo lifts

Patients receiving optimal care for HIV infection can expect to live about as long as those who are uninfected, according to an updated analysis being published in Annals of Internal Medicine.

In 2007, survival estimates for persons receiving HIV care in the Danish HIV Cohort Study were encouraging, but fell short of the general population. At the time, a 25-year-old person with HIV infection not co-infected with hepatitis C virus would be expected to live about 63.9 years, which was still about 12.2 years short of that observed in a sex- and age-matched sample of persons from the general population. Using the same methods used in the previous study, the researchers estimated median survival for persons aged 25 years in 5 time periods from 1995 to 2015. They found that persons with HIV not co-infected with hepatitis C virus could expect to live about to about 73.9 years, compared with about 80.0 years for persons from the general population. The authors attribute survival to receipt of optimal care. However, some persons with HIV infection globally lack access to care and treatment and many others are not reaping the possible benefits even when they do have access. The authors say that these issues should be addressed.

Note: For an embargoed PDF, please contact Cara Graeff. The lead author, Dr. Nicolai Lohse, can be reached directly at niclohse@gmail.com.
-end-
Also new in this issue:

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial

Massimo Colombo, MD; Alessio Aghemo, MD; Hong Liu, PhD; Jie Zhang, PhD; Hadas Dvory-Sobol, PhD; Robert Hyland, DPhil; Chohee Yun, MD; Benedetta Massetto, MD; Diana M. Brainard, MD; John G. McHutchison, MD; Marc Bourlie` re, MD; Markus Peck-Radosavljevic, MD; Michael Manns, MD; and Stanislas Pol, MD

Original Research


Abstract: http://annals.org/aim/article/doi/10.7326/M16-1205

URLs go live when the embargo lifts

In the hot seat: what is this rash after low molecular weight heparin?

Annals Consult Guys

Video: http://annals.org/aim/article/doi/10.7326/W16-0011

URLs go live when the embargo lifts

American College of Physicians

Related Hiv Articles:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.
The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).
Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.
Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.
The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
More HIV News and HIV Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.